NSR AAV-MD

Drug Profile

NSR AAV-MD

Alternative Names: AAV-MD

Latest Information Update: 28 Mar 2017

Price : $50

At a glance

  • Originator NightstaRx
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Macular degeneration

Most Recent Events

  • 23 Mar 2017 Preclinical trials in Macular degeneration in United Kingdom (Intraocular)
  • 23 Mar 2017 NightstaRx plans a phase I/II trial for Macular degeneration in late 2018 (NightstaRx website, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top